CELLAVISION AB (publ) Interim report for the period January 1 - September 30, 2007

Persistently good sales trend

*    Net sales for the period increased by 40% and amounted to SEK
  55.1 million (39.3). Net sales for the third quarter were SEK 21.1
  million (11.6).
*    Operating result for the period was SEK 0.1 million (-7.3), and
  for the third quarter SEK 3.8 million (-2.3).
*    Net result per share amounted to SEK -0.01 million (-0.32) for
  the period.
*    Liquid assets amounted to SEK 16.2 million at the end of the
  period.
*    The new application for bodily fluids was previewed in the USA.

Important events after the reporting period
*    An evaluation of a potential future establishment on the
  Japanese market was initiated.


  CellaVision in summary
                                   Jan 1 - Sept 30  Jan 1 -
                   Q3 2007 Q3 2006       2007       Sept 30 Full year
  (MSEK)                                             2006     2006

  Net sales           21,1    11,6             55,1    39,3      54,8
  Gross profit        11,4     6,4             31,2    21,8      32,0
  Operating result     3,8    -2,3              0,1    -7,3      -8,6
  Net result           3,7    -2,4             -0,2    -7,6      -8,8
  Cash flow            7,5     0,9             -0,5     0,6      -0,8



CEO's comment"CellaVision is closing in on the goal of reaching positive  turnover
during 2007. However, the individual quarterly periods are  difficult
to compare because the company still  is in a phase of rapid  growth,
and very dependent on its  distributors and their success in  sales,"
says Yvonne Mårtensson, CEO of CellaVision."Yet another three Nordic hospitals have decided to use  CellaVison's
products during the  third quarter.  One of them  - Malmö  University
Hospital, our very first client - has upgraded from the DiffMaster to
a CellaVision DM96. In addition to continuing to fortify our position
on markets where we are  already established, we are also  evaluating
the Japanese market. Our products are well in line with the  Japanese
market, which is characterised by large automated laboratories."

Yvonne Mårtensson
CEO CellaVision AB


For more information please contact:
Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail:
yvonne.martensson@cellavision.se
Johan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail:
johan.wennerholm@cellavision.se

Download the report by pressing the link below.